论文部分内容阅读
退行发育的胶质瘤手术后存活期中位值是4-6月,存活到1年者仅1%。手术后加放射疗法存活期中位值可达6-10月,存活1年者不到20%。本文目的是就下述手术后各治疗方法的结果进行比较:(1)多项化学疗法包括环己亚硝脲(CCNU)、长春新硷、氨甲蝶呤4-氨甲基蝶呤(amethopterine)及普鲁苄肼——定名为COMP化学疗法方案;(2)联合采用COMP化学疗法及放射疗法;(3)高伏放射疗法;(4)术后最好的支持疗法作为对照。病例:116例病人按上述治疗方法分成4组。全部病例均经组织学诊断为退行发育的胶质瘤,主要为胶质母细胞瘤、KernohanⅢⅣ级星形细胞瘤等。就成人颅内肿瘤言,这些肿瘤约占1/4。所有病理片均经同一神经病理医生复习分级。各治疗组病例的年龄、症状、病程和肿瘤部位无大区别。
The median survival time of degenerative gliomas after surgery was from April to June and only 1% survived to 1 year. Postoperative radiotherapy survival median of up to 6-10 months, 1 year survival less than 20%. The purpose of this paper is to compare the results of the following treatments following each of the following procedures: (1) Multiple chemotherapies including CCNU, vincristine, methotrexate ) And procarbazine - designated as COMP chemotherapy regimens; (2) combined with COMP chemotherapy and radiation therapy; (3) high-voltradiation; and (4) the best postoperative supportive therapy as a control. Case: 116 patients were divided into 4 groups according to the above treatment. All cases were histologically diagnosed as degenerative glioma, mainly glioblastoma, Kernohan Ⅲ Ⅳ grade astrocytoma and so on. In adult intracranial tumors, these tumors account for about 1/4. All pathology were reviewed by the same neuropathological grading. Each treatment group of patients age, symptoms, course of disease and tumor site no big difference.